Trials / Conditions / Hormone Receptor Positive Malignant Neoplasm of Breast

Hormone Receptor Positive Malignant Neoplasm of Breast

20 registered clinical trials studyying Hormone Receptor Positive Malignant Neoplasm of Breast — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study of Revaree Plus in People With Breast Cancer NCT07042581	Memorial Sloan Kettering Cancer Center	Phase 4
Active Not Recruiting	BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and O NCT06253195	BeiGene	Phase 1
Recruiting	BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli NCT06120283	BeOne Medicines	Phase 1
Recruiting	Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan NCT06805812	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	—
Completed	Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. NCT04483505	Fundacion CRIS de Investigación para Vencer el Cáncer	Phase 1
Unknown	Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer NCT04088110	Fuzhou General Hospital	Phase 2
Withdrawn	Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer NCT04088032	Alison Stopeck	EARLY_Phase 1
Recruiting	Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer NCT04030507	Brigham and Women's Hospital	N/A
Completed	Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast NCT03969121	Kyoto Breast Cancer Research Network	Phase 3
Unknown	Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC NCT03910712	Peking Union Medical College Hospital	Phase 2
Completed	Prospective Thinking in Hormone-Responsive Breast Cancer NCT03594578	Virginia Polytechnic Institute and State University	N/A
Completed	Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer NCT03088527	Stemline Therapeutics, Inc.	Phase 1
Active Not Recruiting	Comparison of the Breast Tumor Microenvironment NCT03165487	Columbia University	—
Completed	Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breas NCT02668666	Oana Danciu, MD	Phase 2
Completed	The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population NCT02347449	Sunnybrook Health Sciences Centre	N/A
Completed	Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizum NCT02248571	iOMEDICO AG	Phase 4
Unknown	Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effect NCT02109913	Amsterdam UMC, location VUmc	N/A
Completed	PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score NCT01617954	Agendia	—
Completed	Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer NCT01589367	Seoul National University Hospital	Phase 2
Unknown	Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer NCT02025712	Organisation for Oncology and Translational Research	Phase 2